Department of Medical Oncology, The First Affiliated Hospital of Hainan Medical University, Haikou, Hainan 570102, China.
Clinical Laboratory Center, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, Anhui 230031, China.
Dis Markers. 2023 Jan 18;2023:3606362. doi: 10.1155/2023/3606362. eCollection 2023.
CEACAM1 has been shown to be aberrantly expressed in a variety of tumors, and modulation of CEACAM1-related signaling pathways has been suggested as a novel approach for cancer immunotherapy in recent years. However, its role in clear cell renal cell carcinoma (ccRCC) is unclear.
The relationship between CEACAM1 and ccRCC was demonstrated based on data from TCGA, GEO, and HPA databases. And the relationship between clinicopathological features and CEACAM1 expression was also assessed. Survival curve analysis was performed to analyze the prognostic relationship between CEACAM1 expression and ccRCC. Protein interaction network analysis was used to analyze the relationship between CEACAM1 and microenvironment-related proteins. In addition, the immunomodulatory role of CEACAM1 in ccRCC was assessed by analyzing CEACAM1 and immune cell infiltration.
The expression of CEACAM1 was lower in ccRCC tissues than in adjacent normal tissues, and its expression level was negatively correlated with tumor size status ( < 0.001), metastasis status ( = 0.009), pathological stage ( = 0.002), gender ( < 0.001), histological grade ( < 0.001), and primary therapy outcome ( = 0.045) of ccRCC. Survival curve analysis showed that ccRCC patients with lower CEACAM1 expression exhibited shorter overall survival ( < 0.001), and CEACAM1 interacted with microenvironmental molecules such as fibronectin and integrins. Furthermore, immune infiltration analysis showed that CEACAM1 expression correlated with CD8 and CD4 T cells, macrophage, neutrophil, and dendritic cell infiltration in ccRCC.
CEACAM1 expression correlates with progression, prognosis, and immune cell infiltration in ccRCC patients, and it may be a promising prognostic biomarker and therapeutic target for ccRCC.
CEACAM1 在多种肿瘤中表达异常,近年来,调节 CEACAM1 相关信号通路被认为是癌症免疫治疗的一种新方法。然而,其在透明细胞肾细胞癌(ccRCC)中的作用尚不清楚。
基于 TCGA、GEO 和 HPA 数据库中的数据,证明了 CEACAM1 与 ccRCC 的关系。并评估了临床病理特征与 CEACAM1 表达之间的关系。通过生存曲线分析,分析了 CEACAM1 表达与 ccRCC 的预后关系。采用蛋白质相互作用网络分析,分析了 CEACAM1 与微环境相关蛋白的关系。此外,通过分析 CEACAM1 与免疫细胞浸润,评估了 CEACAM1 在 ccRCC 中的免疫调节作用。
CEACAM1 在 ccRCC 组织中的表达低于相邻正常组织,其表达水平与肿瘤大小状态呈负相关(<0.001)、转移状态(=0.009)、病理分期(=0.002)、性别(<0.001)、组织学分级(<0.001)和 ccRCC 的主要治疗效果(=0.045)。生存曲线分析表明,CEACAM1 表达较低的 ccRCC 患者总生存期较短(<0.001),CEACAM1 与纤维连接蛋白和整合素等微环境分子相互作用。此外,免疫浸润分析表明,CEACAM1 表达与 ccRCC 中的 CD8 和 CD4 T 细胞、巨噬细胞、中性粒细胞和树突状细胞浸润相关。
CEACAM1 表达与 ccRCC 患者的进展、预后和免疫细胞浸润相关,它可能是 ccRCC 有前途的预后生物标志物和治疗靶点。